Abstract: Hospital-acquired pneumonia (HAP) and health-care-associated pneumonia (HCAP) are leading causes of death, morbidity, and resource utilization in hospitalized patients, and are associated with a broad range of Gram-positive and Gram-negative pathogens. Here, we discuss the different definitions of HAP and HCAP, review current guidelines regarding the treatment of these conditions, highlight the shortcomings of current therapeutic options, and discuss new antibiotic treatments. To optimize therapeutic outcomes in patients with HAP/HCAP, initial antimicrobial treatment must be appropriate and should be given as soon as possible; inappropriate or delayed therapy greatly increases morbidity and mortality. Selection of the most appropriate antimicrobial agent depends on the causative pathogen(s); initial broad-spectrum therapy is commonly recommended and should cover all pathogens that may be present. Treatment selection should also take into consideration the following factors: knowledge of underlying local risk factors for antimicrobial resistance, disease staging, and risk factors related to specific pathogens such as Pseudomonas aeruginosa, Acinetobacter spp., and methicillin-
DEFINITIONS OF HAP AND HCAP
In the USA and Europe, HAP is defined as pneumonia that develops 48 h or more after hospital admission [2, 8, 9] . HAP is distinct from VAP, which arises more than 48- 
TREATMENT OF HAP AND HCAP: CURRENT GUIDELINES AND CONSIDERATIONS
The initial approach to the treatment of patients with HAP and HCAP is often necessarily empirical because complete results of antimicrobial susceptibility testing of the causative pathogens are typically available only after 48-72 h. Appropriate empirical therapy should not be delayed, because inadequate and delayed treatment is associated with increased morbidity and mortality [28, 29] . Successful antimicrobial treatment depends on the use of an agent or regimen that is effective against the causative pathogen(s), and broad-spectrum therapy is often recommended [2] . Antimicrobial therapies that act rapidly reduce the length of hospital stays that in turn reduce resource utilization and health-care system costs [28] .
US and European Guidelines
A summary of key recommendations from the major US and European HAP and HCAP guidelines is provided in Table 1 Gram-positive pathogens [53] . In the pooled all-treated population, intravenous (i.v.)
telavancin 10 mg/kg every 24 h (n = 749) was non-inferior to vancomycin 1 g i.v. every 12 h (n = 754) in terms of clinical cure rate at the follow-up/test-of-cure (TOC) visit [58.9% vs. 59.5%, respectively; 95% confidence interval (CI) for the difference -5.6%, 4.3%]. Moreover, in the subgroup of patients with S. aureus infection (n = 433), telavancin provided a higher clinical cure rate at the TOC visit than vancomycin (78.1% vs. 75.2%; 95% CI for the difference -5.0%, 11.0%). Cure rates were similar in the subgroup of patients with MRSA infection (n = 293; 74.8% and 74.7% for telavancin and vancomycin, respectively; 95% CI for the difference -9.5%, 10.4%).
A post hoc analysis reported similar 28-day survival rates with telavancin and vancomycin (76% and 77%, respectively) [55] , consistent with the mortality data from the original analyses [53] . However, lower survival rates were observed with telavancin compared with vancomycin (59% vs. 70%) in patients with moderate-to-severe renal insufficiency (creatinine clearance \50 mL/min) [54, 55] [54] .
Rates of treatment-emergent adverse events (AEs) were the same for telavancin and vancomycin (both 82%); the most common AEs were diarrhea, anemia, hypokalemia, constipation, and renal impairment. The proportion of patients experiencing serious AEs was higher in the telavancin group than in the vancomycin group (31% vs. 26%). AEs leading to study discontinuation were also higher with telavancin than with vancomycin (8% vs. 5%);
acute renal failure was the most common AE associated with discontinuation in the telavancin group (1.2%) [53] . AEs associated with telavancin included transient elevations in serum creatinine levels, thrombocytopenia and QT prolongation, although to date no cardiovascular events attributed to QT prolongation have been reported [53, [56] [57] [58] . It is recommended that patients receiving telavancin are monitored closely (particularly, their renal function), owing to the associated AEs [45] . The potent activity of telavancin against
Gram-positive HAP pathogens (including MRSA, vancomycin-intermediate S. aureus, and penicillin-resistant S. pneumoniae), and the convenient, once-daily dosing regimen may offer advantages over conventional therapies (Table 2) . However, telavancin is not effective against Gram-negative bacteria [59] . In addition, it is not indicated for patients with severe renal impairment and the risk of nephrotoxicity necessitates constant monitoring of renal function [45] .
Ceftobiprole Medocaril
Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a new-generation, broad-spectrum i. (Table 2) [46, 66] . Ceftobiprole is also approved in Canada. At present, it is not approved in the USA (Table 2) The standard dose of ceftobiprole is 500 mg every 8 h; dose adjustment of ceftobiprole is recommended in patients with moderate or severe renal impairment [46] . 
